These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18055476)

  • 1. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience.
    Coates LC; Cawkwell LS; Ng NW; Bennett AN; Bryer DJ; Fraser AD; Emery P; Marzo-Ortega H
    Ann Rheum Dis; 2008 May; 67(5):717-9. PubMed ID: 18055476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis.
    Coates LC; Cawkwell LS; Ng NW; Bennett AN; Bryer DJ; Fraser AD; Emery P; Marzo-Ortega H
    Rheumatology (Oxford); 2008 Jun; 47(6):897-900. PubMed ID: 18403400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
    Gottlieb A; Korman NJ; Gordon KB; Feldman SR; Lebwohl M; Koo JY; Van Voorhees AS; Elmets CA; Leonardi CL; Beutner KR; Bhushan R; Menter A
    J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
    Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
    Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
    Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Koldingsnes W; Mowinckel P; Kvien TK
    Ann Rheum Dis; 2007 Aug; 66(8):1038-42. PubMed ID: 17213251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination biologic treatment of refractory psoriasis and psoriatic arthritis.
    Cuchacovich R; Garcia-Valladares I; Espinoza LR
    J Rheumatol; 2012 Jan; 39(1):187-93. PubMed ID: 22210681
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study.
    Arkema EV; Neovius M; Joelsson JK; Simard JF; van Vollenhoven RF
    Ann Rheum Dis; 2012 Jul; 71(7):1203-6. PubMed ID: 22504565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.
    Bojke L; Epstein D; Craig D; Rodgers M; Woolacott N; Yang H; Sculpher M
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv39-iv47. PubMed ID: 21859705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy.
    Iannone F; Fanizzi R; Scioscia C; Anelli MG; Lapadula G
    Scand J Rheumatol; 2013; 42(1):41-4. PubMed ID: 22991950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritis.
    Driessen RJ; de Jong EM; Salemink GW; Bürer JH; van de Kerkhof PC; van den Hoogen FH
    Rheumatology (Oxford); 2010 Mar; 49(3):588-91. PubMed ID: 20040525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P
    Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy in current practice of switching between anti-tumour necrosis factor- α agents in spondyloarthropathies.
    Paccou J; Solau-Gervais E; Houvenagel E; Salleron J; Luraschi H; Philippe P; Duquesnoy B; Flipo RM
    Rheumatology (Oxford); 2011 Apr; 50(4):714-20. PubMed ID: 21131271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
    Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.